Login / Signup

IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment.

Shukang ZhaoLianbo LiYoshihiro KomoharaEri MatsubaraYusuke ShinchiAhmad AdawyHiromu YanoCheng PanYukio FujiwaraKoei IkedaShinya SuzuTaizo HibiMakoto Suzuki
Published in: Medical molecular morphology (2024)
Interleukin 32 (IL-32) is a proinflammatory cytokine secreted from several kinds of cancer cells. In the present study, we investigated the significance of IL-32 in lung adenocarcinoma by immunohistochemistry and bioinformatics analysis. IL-32 was positive in cancer cells of 21 cases (9.2%) of total 228 cases. Increased IL-32 gene expression was linked to worse clinical course in TCGA analysis, however, IL-32 expression in immunohistochemistry was not associated to clinical course in our cohort. It was also found that high IL-32 expression was seen in cases with increased lymphocyte infiltration. In vitro studies indicated that IFN-γ induced gene expression of IL-32 and PD1-ligands in lung adenocarcinoma cell lines. IL-32, especially IL-32β, also induced overexpression of PD1-ligands in human monocyte-derived macrophages. Additionally, Cancer-cell-derived IL-32 was elevated by stimulation with anticancer agents. In conclusion, IL-32 potentially induced by inflammatory conditions and anticancer therapy and contribute to immune escape of cancer cells via development the immunosuppressive microenvironment. IL-32 might be a target molecule for anti-cancer therapy.
Keyphrases
  • gene expression
  • cancer therapy
  • poor prognosis
  • squamous cell carcinoma
  • endothelial cells
  • cell death
  • high glucose
  • high resolution
  • long non coding rna
  • lymph node metastasis